Gyre Therapeutics (GYRE) News Today $11.12 +1.13 (+11.31%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Gyre Therapeutics (NASDAQ:GYRE) Stock Price Up 9.1% - What's Next?Gyre Therapeutics (NASDAQ:GYRE) Trading Up 9.1% - Time to Buy?December 17 at 3:09 PM | marketbeat.comGyre Therapeutics, Inc. (NASDAQ:GYRE) Shares Purchased by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. increased its stake in Gyre Therapeutics, Inc. (NASDAQ:GYRE - Free Report) by 392.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 113,648 shares of the company's stock after pDecember 17 at 3:03 AM | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Shares Gap Up - What's Next?Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Up - Here's WhyDecember 16 at 11:43 AM | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Sees Unusually-High Trading Volume - What's Next?December 15 at 3:15 AM | americanbankingnews.comGyre Therapeutics, Inc. (NASDAQ:GYRE) Sees Significant Increase in Short InterestGyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) was the target of a large increase in short interest in November. As of November 30th, there was short interest totalling 549,400 shares, an increase of 36.8% from the November 15th total of 401,700 shares. Approximately 2.5% of the shares of the stock are short sold. Based on an average daily volume of 72,700 shares, the short-interest ratio is currently 7.6 days.December 13, 2024 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Sees Strong Trading Volume - What's Next?Gyre Therapeutics (NASDAQ:GYRE) Sees Strong Trading Volume - Here's What HappenedDecember 13, 2024 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Shares Gap Up - Here's WhyGyre Therapeutics (NASDAQ:GYRE) Shares Gap Up - Here's What HappenedDecember 6, 2024 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Shares Gap Up - Time to Buy?Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Up - What's Next?November 29, 2024 | marketbeat.comGyre Therapeutics Third Quarter 2024 Earnings: EPS: US$0.013 (vs US$0.68 loss in 3Q 2023)November 16, 2024 | finance.yahoo.comGyre Therapeutics, Inc. (NASDAQ:GYRE) Sees Large Decline in Short InterestGyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) was the target of a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 376,600 shares, a decline of 16.1% from the October 15th total of 448,700 shares. Based on an average daily trading volume, of 48,100 shares, the days-to-cover ratio is currently 7.8 days. Currently, 1.6% of the company's stock are sold short.November 16, 2024 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Stock Price Down 7.8% - Here's WhyGyre Therapeutics (NASDAQ:GYRE) Stock Price Down 7.8% - Should You Sell?November 15, 2024 | marketbeat.comGyre Therapeutics Reports Q3 2024 Financial Results and Strategic UpdatesNovember 15, 2024 | markets.businessinsider.comGyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business UpdateNovember 13, 2024 | globenewswire.comGyre: Last patient completes trial evaluating F351 for CHB-liver fibrosisOctober 24, 2024 | markets.businessinsider.comGyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver FibrosisOctober 22, 2024 | globenewswire.comGyre Therapeutics (NASDAQ:GYRE) Trading Down 3.8% - Time to Sell?Gyre Therapeutics (NASDAQ:GYRE) Shares Down 3.8% - Time to Sell?October 22, 2024 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Stock, Short Interest ReportOctober 9, 2024 | benzinga.comGyre Therapeutics, Inc.'s (NASDAQ:GYRE) market cap dropped US$51m last week; Public companies bore the bruntOctober 4, 2024 | finance.yahoo.comGyre Therapeutics (NASDAQ:GYRE) Trading Up 3.3%Gyre Therapeutics (NASDAQ:GYRE) Stock Price Up 3.3%October 3, 2024 | marketbeat.comGyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor ConferenceOctober 1, 2024 | globenewswire.comGyre Therapeutics (NASDAQ:GYRE) Shares Up 4.9%Gyre Therapeutics (NASDAQ:GYRE) Shares Up 4.9%September 16, 2024 | marketbeat.comGyre Therapeutics Inc. (L9S.SG)September 15, 2024 | finance.yahoo.comGyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 5, 2024 | markets.businessinsider.comGyre Therapeutics (NASDAQ:GYRE) Stock Price Down 8.9%Gyre Therapeutics (NASDAQ:GYRE) Trading Down 8.9%September 3, 2024 | marketbeat.comShort Interest in Gyre Therapeutics, Inc. (NASDAQ:GYRE) Grows By 5.4%Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) was the recipient of a significant growth in short interest in August. As of August 15th, there was short interest totalling 336,500 shares, a growth of 5.4% from the July 31st total of 319,300 shares. Based on an average trading volume of 67,200 shares, the short-interest ratio is currently 5.0 days. Currently, 2.0% of the company's shares are sold short.September 2, 2024 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Stock Price Up 4.1%Gyre Therapeutics (NASDAQ:GYRE) Stock Price Up 4.1%August 28, 2024 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Trading Down 6.6%Gyre Therapeutics (NASDAQ:GYRE) Trading Down 6.6%August 27, 2024 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Sees Unusually-High Trading VolumeGyre Therapeutics (NASDAQ:GYRE) Sees Unusually-High Trading VolumeAugust 26, 2024 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Trading 8.2% Higher Gyre Therapeutics (NASDAQ:GYRE) Stock Price Up 8.2%August 19, 2024 | marketbeat.comGyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest UpdateGyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) was the target of a significant increase in short interest in the month of July. As of July 31st, there was short interest totalling 319,300 shares, an increase of 9.5% from the July 15th total of 291,500 shares. Based on an average trading volume of 68,900 shares, the days-to-cover ratio is currently 4.6 days. Currently, 2.0% of the shares of the stock are sold short.August 19, 2024 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Shares Gap Up to $10.40Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Up to $10.40August 14, 2024 | marketbeat.comGyre Therapeutics, Inc.: Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business UpdateAugust 14, 2024 | finanznachrichten.deGyre Therapeutics (NASDAQ:GYRE) Shares Down 3.9% Gyre Therapeutics (NASDAQ:GYRE) Shares Down 3.9%August 13, 2024 | marketbeat.comGyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business UpdateAugust 13, 2024 | globenewswire.comGyre Therapeutics (NASDAQ:GYRE) Shares Up 6.7%Gyre Therapeutics (NASDAQ:GYRE) Stock Price Up 6.7%August 12, 2024 | marketbeat.comGyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of DirectorsAugust 9, 2024 | markets.businessinsider.comGyre Therapeutics to Present at Sidoti Virtual Investor ConferenceAugust 9, 2024 | globenewswire.comGyre Therapeutics (NASDAQ:GYRE) Trading Up 8.4%Gyre Therapeutics (NASDAQ:GYRE) Shares Up 8.4%August 6, 2024 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Shares Down 18.9% Gyre Therapeutics (NASDAQ:GYRE) Trading Down 18.9%August 5, 2024 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Stock Price Down 8.4%Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 8.4%July 30, 2024 | marketbeat.comGyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest Up 67.9% in JulyGyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) was the target of a large increase in short interest during the month of July. As of July 15th, there was short interest totalling 291,500 shares, an increase of 67.9% from the June 30th total of 173,600 shares. Currently, 1.9% of the company's stock are short sold. Based on an average daily volume of 72,000 shares, the short-interest ratio is presently 4.0 days.July 26, 2024 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Stock Price Down 4.3%Gyre Therapeutics (NASDAQ:GYRE) Trading Down 4.3%July 19, 2024 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Trading Down 4.3%Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 4.3%July 8, 2024 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Stock Price Up 3.7%Gyre Therapeutics (NASDAQ:GYRE) Trading 3.7% HigherJuly 5, 2024 | marketbeat.comGyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest Down 7.0% in JuneGyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) was the target of a significant decline in short interest during the month of June. As of June 15th, there was short interest totalling 189,100 shares, a decline of 7.0% from the May 31st total of 203,300 shares. Approximately 1.2% of the company's stock are short sold. Based on an average daily volume of 63,300 shares, the days-to-cover ratio is presently 3.0 days.July 3, 2024 | marketbeat.comGyre Therapeutics Announces China's NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated ThrombocytopeniaJuly 2, 2024 | globenewswire.comGyre Therapeutics (NASDAQ:GYRE) Shares Down 4% After Insider SellingGyre Therapeutics (NASDAQ:GYRE) Trading Down 4% Following Insider SellingJuly 2, 2024 | marketbeat.comInsider Selling: Gyre Therapeutics, Inc. (NASDAQ:GYRE) Director Sells 3,452 Shares of StockJuly 2, 2024 | insidertrades.comNassim Usman Sells 3,452 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) StockGyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) Director Nassim Usman sold 3,452 shares of the firm's stock in a transaction dated Friday, June 28th. The shares were sold at an average price of $12.00, for a total transaction of $41,424.00. Following the completion of the transaction, the director now directly owns 1,636 shares in the company, valued at approximately $19,632. The sale was disclosed in a document filed with the SEC, which is accessible through this link.July 1, 2024 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Trading Down 8.3%Gyre Therapeutics (NASDAQ:GYRE) Trading Down 8.3%June 26, 2024 | marketbeat.com Get Gyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address How to piss off your liberal friends… and profit from it (Ad)Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies. To get the full details on the fake “energy crisis” of America, watch this now GYRE Media Mentions By Week GYRE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GYRE News Sentiment▼0.900.71▲Average Medical News Sentiment GYRE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GYRE Articles This Week▼71▲GYRE Articles Average Week Get Gyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Organon & Co. News Today PTC Therapeutics News Today Rhythm Pharmaceuticals News Today MoonLake Immunotherapeutics News Today ImmunityBio News Today Janux Therapeutics News Today Verona Pharma News Today Xenon Pharmaceuticals News Today Zai Lab News Today ACADIA Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GYRE) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
